These studies should analyze conventional and advanced MRI features together with GBM molecular characteristics that may affect treatment response (i.e., MGMT methylation, IDH mutation, and TERT promoter mutation status) and include an external validation cohort. This evidence concerns the gene TERT and glioblastoma.